Literature DB >> 17539696

Behavioral therapy for weight loss in patients with schizophrenia.

Rohan Ganguli1.   

Abstract

Compared with the general population, individuals with schizophrenia demonstrate an increased prevalence of obesity. While most antipsychotics are associated with weight gain, certain second-generation antipsychotics (SGAs) appear to be especially problematic. Weight gain and obesity are highly distressing to these patients, can reduce treatment adherence, and may increase the relative risk of serious medical conditions and all-cause premature mortality. The selection of an antipsychotic on the basis of its effectiveness and relative side effect profile is recognized as an important initial consideration in the treatment of schizophrenia. However, less is known regarding the efficacy of dietary, pharmacologic, and behavioral therapy in reducing antipsychotic-related weight gain and obesity. Behavioral therapy, in particular, is understudied, and there are relatively few controlled trials of its effectiveness in reducing SGA-induced weight gain. Although weight loss resulting from behavioral therapy has been observed mostly as a result of effective short-term interventions, controlled behavioral studies do exist to suggest that weight can be controlled long term. In addition, a small pilot study in patients with schizophrenia or schizoaffective disorder recently demonstrated that behavioral therapy that utilizes stepped interventions, involving body weight self-monitoring, diet, and exercise, can prevent weight gain in patients initiating treatment with SGAs. Additional studies of behavioral therapy for long-term weight control in patients with schizophrenia and other forms of severe mental illness are warranted.

Entities:  

Mesh:

Year:  2007        PMID: 17539696

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

1.  The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders.

Authors:  Vibeke Porsdal; Catherine Beal; Ole Kristian Kleivenes; Egil W Martinsen; Eva Lindström; Harriet Nilsson; Pär Svanborg
Journal:  BMC Psychiatry       Date:  2010-06-10       Impact factor: 3.630

2.  Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial.

Authors:  Kornelia Gillhoff; Jens Gaab; Luljeta Emini; Caroline Maroni; Joachim Tholuck; Waldemar Greil
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

3.  Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.

Authors:  T Scott Stroup; Matthew J Byerly; Henry A Nasrallah; Neepa Ray; Ahsan Y Khan; J Steven Lamberti; Ira D Glick; Richard M Steinbook; Joseph P McEvoy; Robert M Hamer
Journal:  Schizophr Res       Date:  2013-02-21       Impact factor: 4.939

4.  Interventions for the metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

5.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

6.  A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Authors:  T Scott Stroup; Joseph P McEvoy; Kimberly D Ring; Robert H Hamer; Lisa M LaVange; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Abraham M Nussbaum; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2011-07-18       Impact factor: 18.112

7.  Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.

Authors:  Richard S E Keefe; Sophia Vinogradov; Alice Medalia; Peter F Buckley; Stanley N Caroff; Deepak C D'Souza; Phillip D Harvey; Karen A Graham; Robert M Hamer; Stephen M Marder; Del D Miller; Stephen J Olson; Jayendra K Patel; Dawn Velligan; Trina M Walker; Adam J Haim; T Scott Stroup
Journal:  J Clin Psychiatry       Date:  2012-05-15       Impact factor: 4.384

Review 8.  Addressing cardiometabolic risk during treatment with antipsychotic medications.

Authors:  Jonathan M Amiel; Christina V Mangurian; Rohan Ganguli; John W Newcomer
Journal:  Curr Opin Psychiatry       Date:  2008-11       Impact factor: 4.741

9.  Treatment of obesity and disability in schizophrenia.

Authors:  Martin Strassnig; Philip D Harvey
Journal:  Innov Clin Neurosci       Date:  2013-07

10.  Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

Authors:  Virginia L Stauffer; Ilya Lipkovich; Vicki Poole Hoffmann; Alexandra N Heinloth; H Scott McGregor; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2009-03-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.